U.S. still top spot for Phase I trials, but China leads in I&I, metabolic disease

The U.S. and China host more Phase I trials than other countries by a wide margin, according to BioCentury’s analysis of study starts in 2021-25. Between the two, the U.S. had the most Phase I activity overall, but China surpassed the U.S. in I&I and metabolic diseases.

BioCentury analyzed Phase I trials in the ClinicalTrials.gov database that started in 2021-25, including those that remain active or ran to completion. The data in this report include studies with disclosed site locations and indications.  (A full analysis of the data will be presented at the upcoming 26th Bio€quity Europe conference, May 3-5, Prague)...